Loading…

Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review

Energy homeostasis is achieved by the integration of peripheral metabolic signals by the neural circuits involving specific hypothalamic nuclei and brain stem regions. These neural circuits mediate many of the effects of the adipocyte-derived hormone leptin and gut-derived hormone ghrelin. The forme...

Full description

Saved in:
Bibliographic Details
Published in:Schizophrenia bulletin 2008-11, Vol.34 (6), p.1189-1199
Main Authors: Sentissi, Othman, Epelbaum, Jacques, Olié, Jean-Pierre, Poirier, Marie-France
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43
cites cdi_FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43
container_end_page 1199
container_issue 6
container_start_page 1189
container_title Schizophrenia bulletin
container_volume 34
creator Sentissi, Othman
Epelbaum, Jacques
Olié, Jean-Pierre
Poirier, Marie-France
description Energy homeostasis is achieved by the integration of peripheral metabolic signals by the neural circuits involving specific hypothalamic nuclei and brain stem regions. These neural circuits mediate many of the effects of the adipocyte-derived hormone leptin and gut-derived hormone ghrelin. The former is strongly anorexigenic while the latter is the only orexigenic agent active when administered by a peripheral route. Abnormal regulation of these 2 antagonistic regulatory peptides in patients with schizophrenia could play a role in the impairment in the regulation of food intake and energy balance. This bibliographical analysis aims to compare 27 prospective and cross-sectional studies published on circulating leptin and ghrelin levels during acute and chronic administration of antipsychotics treatment, especially atypical ones. Fasting morning leptin levels of schizophrenic patients increase rapidly in the first 2 weeks after atypical antipsychotic (AAP) treatment (mostly olanzapine and clozapine) and remain somehow elevated after that period up to several months. On the contrary, conventional antipsychotics (such as haloperidol) do not interfere with leptin levels. In contrast to leptin, fasting morning ghrelin levels decrease during the first few weeks after the beginning of AAPs treatment while they increase in the longer run. Surprisingly, body weight gain and correlations between the variation of these 2 peptides and adiposity and metabolism-related parameters such as the body mass index and abdominal perimeter were not systematically considered. Finally, an objective evaluation of feeding behavior during antipsychotic treatment remains to be determined.
doi_str_mv 10.1093/schbul/sbm141
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2632509</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/schbul/sbm141</oup_id><sourcerecordid>1575905961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43</originalsourceid><addsrcrecordid>eNqFkc2LFDEQxYMo7jh69CpBELy0m69Ouj0Iw-66CgOKrngM6UxlO0tPuk3SI-tfv5EeVj15qqLej6pHPYSeU_KGkpafJtt383Cauj0V9AFaUSXqiipCH6IVqRtZKUnFCXqS0g0hVLSSPUYntKGyZpKt0LCFKfuATdjhyz7CUPotHGBIuHSfTfYQcsLffe7xV9v7X-NUqOANPp-jD9f43DsHZZLxJmQ_pVvbj9nbhK8imLwvwlu8wV_g4OHnU_TImSHBs2Ndo2_vL67OPlTbT5cfzzbbygpV54q5VrWupXXbsRrUjhlJlQTXNLITO-ukI5xLSQCU48woxazqKONWOGeNFXyN3i17p7nbw84WE9EMeop-b-KtHo3X_yrB9_p6PGgmOavLV9fo5XFBHH_MkLK-GecYimfNGK9F2zBVoGqBbBxTiuDuD1Cif2ejl2z0kk3hX_zt6g99DKMAr46ASdYMLppgfbrnGGk455QX7vXCjfP0n5t3CTqpjQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223549827</pqid></control><display><type>article</type><title>Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review</title><source>Open Access: PubMed Central</source><source>Oxford Journals Online</source><creator>Sentissi, Othman ; Epelbaum, Jacques ; Olié, Jean-Pierre ; Poirier, Marie-France</creator><creatorcontrib>Sentissi, Othman ; Epelbaum, Jacques ; Olié, Jean-Pierre ; Poirier, Marie-France</creatorcontrib><description>Energy homeostasis is achieved by the integration of peripheral metabolic signals by the neural circuits involving specific hypothalamic nuclei and brain stem regions. These neural circuits mediate many of the effects of the adipocyte-derived hormone leptin and gut-derived hormone ghrelin. The former is strongly anorexigenic while the latter is the only orexigenic agent active when administered by a peripheral route. Abnormal regulation of these 2 antagonistic regulatory peptides in patients with schizophrenia could play a role in the impairment in the regulation of food intake and energy balance. This bibliographical analysis aims to compare 27 prospective and cross-sectional studies published on circulating leptin and ghrelin levels during acute and chronic administration of antipsychotics treatment, especially atypical ones. Fasting morning leptin levels of schizophrenic patients increase rapidly in the first 2 weeks after atypical antipsychotic (AAP) treatment (mostly olanzapine and clozapine) and remain somehow elevated after that period up to several months. On the contrary, conventional antipsychotics (such as haloperidol) do not interfere with leptin levels. In contrast to leptin, fasting morning ghrelin levels decrease during the first few weeks after the beginning of AAPs treatment while they increase in the longer run. Surprisingly, body weight gain and correlations between the variation of these 2 peptides and adiposity and metabolism-related parameters such as the body mass index and abdominal perimeter were not systematically considered. Finally, an objective evaluation of feeding behavior during antipsychotic treatment remains to be determined.</description><identifier>ISSN: 0586-7614</identifier><identifier>EISSN: 1745-1701</identifier><identifier>DOI: 10.1093/schbul/sbm141</identifier><identifier>PMID: 18165262</identifier><identifier>CODEN: SCZBB3</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Appetite - drug effects ; Biological and medical sciences ; Body Weight - drug effects ; Cross-Sectional Studies ; Drug toxicity and drugs side effects treatment ; Eating - drug effects ; Energy Metabolism - drug effects ; Female ; Ghrelin - blood ; Homeostasis - drug effects ; Humans ; Leptin - blood ; Male ; Medical sciences ; Middle Aged ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Pharmacology. Drug treatments ; Prospective Studies ; Regular ; Schizophrenia - blood ; Schizophrenia - drug therapy ; Young Adult</subject><ispartof>Schizophrenia bulletin, 2008-11, Vol.34 (6), p.1189-1199</ispartof><rights>Published by Oxford University Press 2007. 2008</rights><rights>2009 INIST-CNRS</rights><rights>Published by Oxford University Press 2007.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43</citedby><cites>FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2632509/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2632509/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20833313$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18165262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sentissi, Othman</creatorcontrib><creatorcontrib>Epelbaum, Jacques</creatorcontrib><creatorcontrib>Olié, Jean-Pierre</creatorcontrib><creatorcontrib>Poirier, Marie-France</creatorcontrib><title>Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review</title><title>Schizophrenia bulletin</title><addtitle>Schizophr Bull</addtitle><description>Energy homeostasis is achieved by the integration of peripheral metabolic signals by the neural circuits involving specific hypothalamic nuclei and brain stem regions. These neural circuits mediate many of the effects of the adipocyte-derived hormone leptin and gut-derived hormone ghrelin. The former is strongly anorexigenic while the latter is the only orexigenic agent active when administered by a peripheral route. Abnormal regulation of these 2 antagonistic regulatory peptides in patients with schizophrenia could play a role in the impairment in the regulation of food intake and energy balance. This bibliographical analysis aims to compare 27 prospective and cross-sectional studies published on circulating leptin and ghrelin levels during acute and chronic administration of antipsychotics treatment, especially atypical ones. Fasting morning leptin levels of schizophrenic patients increase rapidly in the first 2 weeks after atypical antipsychotic (AAP) treatment (mostly olanzapine and clozapine) and remain somehow elevated after that period up to several months. On the contrary, conventional antipsychotics (such as haloperidol) do not interfere with leptin levels. In contrast to leptin, fasting morning ghrelin levels decrease during the first few weeks after the beginning of AAPs treatment while they increase in the longer run. Surprisingly, body weight gain and correlations between the variation of these 2 peptides and adiposity and metabolism-related parameters such as the body mass index and abdominal perimeter were not systematically considered. Finally, an objective evaluation of feeding behavior during antipsychotic treatment remains to be determined.</description><subject>Adult</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Appetite - drug effects</subject><subject>Biological and medical sciences</subject><subject>Body Weight - drug effects</subject><subject>Cross-Sectional Studies</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Eating - drug effects</subject><subject>Energy Metabolism - drug effects</subject><subject>Female</subject><subject>Ghrelin - blood</subject><subject>Homeostasis - drug effects</subject><subject>Humans</subject><subject>Leptin - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Regular</subject><subject>Schizophrenia - blood</subject><subject>Schizophrenia - drug therapy</subject><subject>Young Adult</subject><issn>0586-7614</issn><issn>1745-1701</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqFkc2LFDEQxYMo7jh69CpBELy0m69Ouj0Iw-66CgOKrngM6UxlO0tPuk3SI-tfv5EeVj15qqLej6pHPYSeU_KGkpafJtt383Cauj0V9AFaUSXqiipCH6IVqRtZKUnFCXqS0g0hVLSSPUYntKGyZpKt0LCFKfuATdjhyz7CUPotHGBIuHSfTfYQcsLffe7xV9v7X-NUqOANPp-jD9f43DsHZZLxJmQ_pVvbj9nbhK8imLwvwlu8wV_g4OHnU_TImSHBs2Ndo2_vL67OPlTbT5cfzzbbygpV54q5VrWupXXbsRrUjhlJlQTXNLITO-ukI5xLSQCU48woxazqKONWOGeNFXyN3i17p7nbw84WE9EMeop-b-KtHo3X_yrB9_p6PGgmOavLV9fo5XFBHH_MkLK-GecYimfNGK9F2zBVoGqBbBxTiuDuD1Cif2ejl2z0kk3hX_zt6g99DKMAr46ASdYMLppgfbrnGGk455QX7vXCjfP0n5t3CTqpjQ</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>Sentissi, Othman</creator><creator>Epelbaum, Jacques</creator><creator>Olié, Jean-Pierre</creator><creator>Poirier, Marie-France</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope></search><sort><creationdate>20081101</creationdate><title>Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review</title><author>Sentissi, Othman ; Epelbaum, Jacques ; Olié, Jean-Pierre ; Poirier, Marie-France</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Appetite - drug effects</topic><topic>Biological and medical sciences</topic><topic>Body Weight - drug effects</topic><topic>Cross-Sectional Studies</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Eating - drug effects</topic><topic>Energy Metabolism - drug effects</topic><topic>Female</topic><topic>Ghrelin - blood</topic><topic>Homeostasis - drug effects</topic><topic>Humans</topic><topic>Leptin - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Regular</topic><topic>Schizophrenia - blood</topic><topic>Schizophrenia - drug therapy</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sentissi, Othman</creatorcontrib><creatorcontrib>Epelbaum, Jacques</creatorcontrib><creatorcontrib>Olié, Jean-Pierre</creatorcontrib><creatorcontrib>Poirier, Marie-France</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Schizophrenia bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sentissi, Othman</au><au>Epelbaum, Jacques</au><au>Olié, Jean-Pierre</au><au>Poirier, Marie-France</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review</atitle><jtitle>Schizophrenia bulletin</jtitle><addtitle>Schizophr Bull</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>34</volume><issue>6</issue><spage>1189</spage><epage>1199</epage><pages>1189-1199</pages><issn>0586-7614</issn><eissn>1745-1701</eissn><coden>SCZBB3</coden><abstract>Energy homeostasis is achieved by the integration of peripheral metabolic signals by the neural circuits involving specific hypothalamic nuclei and brain stem regions. These neural circuits mediate many of the effects of the adipocyte-derived hormone leptin and gut-derived hormone ghrelin. The former is strongly anorexigenic while the latter is the only orexigenic agent active when administered by a peripheral route. Abnormal regulation of these 2 antagonistic regulatory peptides in patients with schizophrenia could play a role in the impairment in the regulation of food intake and energy balance. This bibliographical analysis aims to compare 27 prospective and cross-sectional studies published on circulating leptin and ghrelin levels during acute and chronic administration of antipsychotics treatment, especially atypical ones. Fasting morning leptin levels of schizophrenic patients increase rapidly in the first 2 weeks after atypical antipsychotic (AAP) treatment (mostly olanzapine and clozapine) and remain somehow elevated after that period up to several months. On the contrary, conventional antipsychotics (such as haloperidol) do not interfere with leptin levels. In contrast to leptin, fasting morning ghrelin levels decrease during the first few weeks after the beginning of AAPs treatment while they increase in the longer run. Surprisingly, body weight gain and correlations between the variation of these 2 peptides and adiposity and metabolism-related parameters such as the body mass index and abdominal perimeter were not systematically considered. Finally, an objective evaluation of feeding behavior during antipsychotic treatment remains to be determined.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>18165262</pmid><doi>10.1093/schbul/sbm141</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0586-7614
ispartof Schizophrenia bulletin, 2008-11, Vol.34 (6), p.1189-1199
issn 0586-7614
1745-1701
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2632509
source Open Access: PubMed Central; Oxford Journals Online
subjects Adult
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Antipsychotics
Appetite - drug effects
Biological and medical sciences
Body Weight - drug effects
Cross-Sectional Studies
Drug toxicity and drugs side effects treatment
Eating - drug effects
Energy Metabolism - drug effects
Female
Ghrelin - blood
Homeostasis - drug effects
Humans
Leptin - blood
Male
Medical sciences
Middle Aged
Miscellaneous (drug allergy, mutagens, teratogens...)
Pharmacology. Drug treatments
Prospective Studies
Regular
Schizophrenia - blood
Schizophrenia - drug therapy
Young Adult
title Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T06%3A40%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Leptin%20and%20Ghrelin%20Levels%20in%20Patients%20With%20Schizophrenia%20During%20Different%20Antipsychotics%20Treatment:%20A%20Review&rft.jtitle=Schizophrenia%20bulletin&rft.au=Sentissi,%20Othman&rft.date=2008-11-01&rft.volume=34&rft.issue=6&rft.spage=1189&rft.epage=1199&rft.pages=1189-1199&rft.issn=0586-7614&rft.eissn=1745-1701&rft.coden=SCZBB3&rft_id=info:doi/10.1093/schbul/sbm141&rft_dat=%3Cproquest_pubme%3E1575905961%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=223549827&rft_id=info:pmid/18165262&rft_oup_id=10.1093/schbul/sbm141&rfr_iscdi=true